Drug Profile
Itraconazole - Mayne Pharma
Alternative Names: Itragerm; Itraisdin; Lozanoc; Mytra; SUBA; SUBA®-itraconazole; Subacap; TolsuraLatest Information Update: 21 Dec 2023
Price :
$50
*
At a glance
- Originator Mayne Pharma Group
- Developer INHIBITOR Therapeutics; Mayne Pharma Group
- Class Antiasthmatics; Antifungals; Antineoplastics; Azoles; Chlorobenzenes; Dioxoles; Piperazines; Small molecules; Triazoles
- Mechanism of Action 14-alpha demethylase inhibitors; Cytochrome P 450 enzyme system inhibitors; Hedgehog cell-signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Mycoses
Highest Development Phases
- Marketed Mycoses
- Phase II Basal cell cancer; Prostate cancer
- Preclinical Lung cancer
Most Recent Events
- 19 Dec 2023 Efficacy and safety data from a phase IIb SCORING trial in Basal cell cancer released by Inhibitor Therapeutics
- 16 Oct 2023 Inhibitor Therapeutics plans a meet with US FDA (Inhibitor Therapeutics pipeline, October 2023)
- 18 Apr 2023 Phase-II clinical trials in Prostate cancer (Metastatic disease, Late-stage disease, Combination therapy, Hormone refractory) in USA, European Union (PO), prior to April 2023 (INHIBITOR Therapeutics pipeline, April 2023)